Pharmacogenetic Study Of Apo A5, Cetp And Mthfr Polymorphisms On Fenofibrate Therapy In Tunisians Type 2 Diabetic Patients | 6091
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Pharmacogenetic Study of Apo A5, Cetp and Mthfr Polymorphisms on Fenofibrate Therapy in Tunisians Type 2 Diabetic Patients

International Conference & Exihibition On Analytical and Bioanalytical Techniques - 2010

Mohamed Hammami, Raja Chabaa, Nadia Koubaa, Sonia Hammami, Maha Smaoui, Nabil Attia, Amel Nakbi, Khaldoun Ben Hamda

ScientificTracks Abstracts: J Anal Bioanal Techniques

DOI: 10.4172/2155-9872.1000001

Fibrates act to attenuate atherogenic dyslipidemia in type 2 diabetic patients. However an increase of serum homocysteine (tHcy) after fenofibrate treatment has been reported, compromising its cardiovascular benefit. Polymorphisms in candidate genes related to lipid, lipoprotein and tHcy metabolisms were suspected to influence this response. The association between polymorphisms in cholesteryl ester transfer protein (CETP), apolipoprotein A5 (apo A 5), and methylenetetrahydrofolate reductase (MTHFR) genes in response to fenofibrate treatment ((200 M) for 4 weeks was evaluated in twenty one type 2 diabetic patients. After fenofibrate use a significant decrease of TG level (29%) and a decrease of total cholesterol (p = 0.081) and CETP activity (p = 0.089) were noted. However, the HDL-C concentration has increased (p= 0.081) while LDL-C levels did not vary. Moreover, the prevalence of hyperhomocysteinemia, rose to 100%. Both apo A5 TT and TC carriers showed significant decrease of TG levels. Whereas the HDL-C variation is better in TT genotype (23.5% vs -1.3% for TT and TC respectively; p = 0.062). The decrease of TG levels after fenofibrate treatment is more important in B1B1 than in B2B2 genotype of CETP polymorphism. Only B1B1 homozygous showed a decrease of CETP activity and an increase of HDL-C. After fenofibrate use, the increase of tHcy levels was more important in MTHFR T carriers than in CC homozygous (39.97 � 14.77 vs. 28.02 � 8.59 μmol/l, respectively). Pharmacogenomic studies have a great economic and health interest for a better treatment of type 2 diabetic patients.